NextWave gets $45M, gets ready to introduce ADHD drug

NextWave Pharmaceuticals, a drug-delivery company based in Cupertino, CA, has attracted $45 million in Series C financing. The company said in a release that it will use the money to commercialize recently launched Nexiclon XR to treat hypertension and get ready to introduce an extended-release liquid methylphenidate for Attention Deficit Hyperactivity Disorder currently under review by the FDA.

Co-led by new investors Panorama Capital and Bay City Capital, the financing round included Kearny Venture Partners as well as NextWave's current investors: Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.

"NextWave is poised for near-term success," said Gaurav Aggarwal, partner at Panorama Capital, in a statement. "In addition to NextWave's filed NDA and promising pipeline, we are excited to back such a strong executive team with a depth of industry-specific experience and record of successfully bringing products to the market. NextWave's extended-release liquid methylphenidate will compete in a multi-billion dollar market that continues to grow."

- take a look at the NextWave release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.